Cell line · CVCL_3326
Papers32
1 to 20 of 32
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. | Cell Commun Signal | 2024 | Its Methods give the RRID and name the line | PubMed | |
| GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. | Leukemia | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. | Sci Adv | 2022 | Its Methods give the RRID and name the line | PubMed | |
| NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. | Mol Cell | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. | Immunity | 2021 | Its Methods give the RRID and name the line | PubMed | |
| IKKε and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKε/TBK1 inhibitor to repress NF-κB and IL-10 signalling. | J Cell Mol Med | 2020 | Its Methods give the RRID and name the line | PubMed | |
| A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. | Elife | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line. | Mol Med Rep | 2019 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines. | BMC Cancer | 2018 | Cellosaurus cites it | PubMed | |
| Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. | Clin Cancer Res | 2018 | Cellosaurus cites it | PubMed | |
| Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. | Oncotarget | 2018 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3326/papers